Kaleido Biosciences Inc

NASDAQ:KLDO   3:59:44 PM EDT
6.69
-0.20 (-2.90%)
Other Pre-Announcement

Kaleido Biosciences Provides Update On KB109 Clinical Data Timeline

Published: 10/06/2020 11:39 GMT
(KLDO) - Kaleido Biosciences Provides Update on Kb109 Clinical Data Timeline.
Kaleido Biosciences - Updated Projections for Enrollment of Multi-center K031 Clinical Study Indicated Top-line Data Will Be Available in Q1 of 2021.
Kaleido Biosciences - Continue to Expect Preclinical Data From Co's Immuno-oncology, Cardiometabolic and Liver Diseases Programs This Quarter.
Kaleido Biosciences - Results of Our K032 Clinical Study of Kb109 Continue to Be Expected in Q1 of 2021.
Kaleido Biosciences - Guidance for Co's Other Programs is Unchanged.